JP2021088575A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021088575A5 JP2021088575A5 JP2021021155A JP2021021155A JP2021088575A5 JP 2021088575 A5 JP2021088575 A5 JP 2021088575A5 JP 2021021155 A JP2021021155 A JP 2021021155A JP 2021021155 A JP2021021155 A JP 2021021155A JP 2021088575 A5 JP2021088575 A5 JP 2021088575A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- administered
- item
- methanesulfonate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 29
- 206010021518 Impaired gastric emptying Diseases 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 208000024891 symptom Diseases 0.000 claims description 8
- 208000001288 gastroparesis Diseases 0.000 claims description 7
- 201000006549 dyspepsia Diseases 0.000 claims description 6
- 238000007913 intrathecal administration Methods 0.000 claims description 6
- 206010028813 Nausea Diseases 0.000 claims description 5
- 206010047700 Vomiting Diseases 0.000 claims description 5
- BQDBKDMTIJBJLA-UHFFFAOYSA-N metopimazine Chemical compound C12=CC(S(=O)(=O)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCC(C(N)=O)CC1 BQDBKDMTIJBJLA-UHFFFAOYSA-N 0.000 claims description 5
- 230000008693 nausea Effects 0.000 claims description 5
- 230000008673 vomiting Effects 0.000 claims description 5
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 4
- 208000004998 Abdominal Pain Diseases 0.000 claims description 3
- 206010000060 Abdominal distension Diseases 0.000 claims description 3
- 206010010774 Constipation Diseases 0.000 claims description 3
- 206010012735 Diarrhoea Diseases 0.000 claims description 3
- 241000792859 Enema Species 0.000 claims description 3
- 230000004596 appetite loss Effects 0.000 claims description 3
- 208000024330 bloating Diseases 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000007920 enema Substances 0.000 claims description 3
- 229940095399 enema Drugs 0.000 claims description 3
- 208000019017 loss of appetite Diseases 0.000 claims description 3
- 235000021266 loss of appetite Nutrition 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000003889 eye drop Substances 0.000 claims description 2
- 229940012356 eye drops Drugs 0.000 claims description 2
- 238000001361 intraarterial administration Methods 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 235000015927 pasta Nutrition 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 6
- 229960000767 metopimazine Drugs 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000000034 method Methods 0.000 description 49
- 150000001875 compounds Chemical class 0.000 description 25
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 24
- 208000012902 Nervous system disease Diseases 0.000 description 14
- 210000000105 enteric nervous system Anatomy 0.000 description 14
- 229940123736 Decarboxylase inhibitor Drugs 0.000 description 12
- 239000003954 decarboxylase inhibitor Substances 0.000 description 12
- 229960003638 dopamine Drugs 0.000 description 12
- 125000000217 alkyl group Chemical group 0.000 description 10
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 6
- 125000005843 halogen group Chemical group 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 230000008499 blood brain barrier function Effects 0.000 description 4
- 210000001218 blood-brain barrier Anatomy 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 229940123603 Dopamine D2 receptor antagonist Drugs 0.000 description 3
- 229960004205 carbidopa Drugs 0.000 description 3
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical group NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 description 3
- 239000000442 dopamine 2 receptor blocking agent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000006876 Multiple Endocrine Neoplasia Type 2b Diseases 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- DYMRYCZRMAHYKE-UHFFFAOYSA-N n-diazonitramide Chemical compound [O-][N+](=O)N=[N+]=[N-] DYMRYCZRMAHYKE-UHFFFAOYSA-N 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 0 *c(cc1)cc2c1SC1=CC=CCC1N2I=* Chemical compound *c(cc1)cc2c1SC1=CC=CCC1N2I=* 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 208000027601 Inner ear disease Diseases 0.000 description 1
- 206010073659 Intestinal neuronal dysplasia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000005890 Neuroma Diseases 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229940082988 antihypertensives serotonin antagonists Drugs 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000000952 serotonin receptor agonist Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000027491 vestibular disease Diseases 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261745734P | 2012-12-24 | 2012-12-24 | |
| US61/745,734 | 2012-12-24 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018213361A Division JP2019048848A (ja) | 2012-12-24 | 2018-11-14 | Ｇｉ管障害を治療するための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021088575A JP2021088575A (ja) | 2021-06-10 |
| JP2021088575A5 true JP2021088575A5 (enExample) | 2021-08-19 |
Family
ID=51021982
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015549742A Active JP6154025B2 (ja) | 2012-12-24 | 2013-12-19 | Ｇｉ管障害を治療するための方法 |
| JP2017108370A Active JP6437593B2 (ja) | 2012-12-24 | 2017-05-31 | Ｇｉ管障害を治療するための方法 |
| JP2018213361A Pending JP2019048848A (ja) | 2012-12-24 | 2018-11-14 | Ｇｉ管障害を治療するための方法 |
| JP2021021155A Pending JP2021088575A (ja) | 2012-12-24 | 2021-02-12 | Ｇｉ管障害を治療するための方法 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015549742A Active JP6154025B2 (ja) | 2012-12-24 | 2013-12-19 | Ｇｉ管障害を治療するための方法 |
| JP2017108370A Active JP6437593B2 (ja) | 2012-12-24 | 2017-05-31 | Ｇｉ管障害を治療するための方法 |
| JP2018213361A Pending JP2019048848A (ja) | 2012-12-24 | 2018-11-14 | Ｇｉ管障害を治療するための方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (7) | US9132134B2 (enExample) |
| EP (1) | EP2934540B1 (enExample) |
| JP (4) | JP6154025B2 (enExample) |
| CN (1) | CN104884064A (enExample) |
| AU (1) | AU2013370966A1 (enExample) |
| BR (1) | BR112015015258A2 (enExample) |
| CA (2) | CA2893427C (enExample) |
| ES (1) | ES2955693T3 (enExample) |
| WO (1) | WO2014105655A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9107815B2 (en) * | 2008-02-22 | 2015-08-18 | Allergan, Inc. | Sustained release poloxamer containing pharmaceutical compositions |
| AU2013370966A1 (en) * | 2012-12-24 | 2015-06-18 | Neurogastrx, Inc. | Methods for treating GI tract disorders |
| WO2015200369A1 (en) | 2014-06-24 | 2015-12-30 | Neurogastrx, Inc. | Prodrugs of metopimazine |
| US9695138B1 (en) | 2016-10-17 | 2017-07-04 | Acenda Pharma, Inc. | Phenothiazine derivatives and methods of use thereof |
| CN109053716B (zh) * | 2018-09-26 | 2021-01-08 | 暨明医药科技（苏州）有限公司 | 一种制备美托哌丙嗪的新工艺 |
| US10836757B1 (en) * | 2020-04-02 | 2020-11-17 | Neurogastrx, Inc. | Polymorphic forms of metopimazine |
| WO2022146970A1 (en) * | 2020-12-29 | 2022-07-07 | Neurogastrx, Inc. | Methods of metabolizing metopimazine and its salts |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1092476B (de) | 1958-04-24 | 1960-11-10 | Rhone Poulenc Sa | Verfahren zur Herstellung von Phenthiazinderivaten |
| BE786583A (fr) | 1971-07-21 | 1973-01-22 | Rhone Poulenc Sa | Nouveaux derives de la phenothiazine, leur preparation et les compositions qui les contiennent |
| IT1202370B (it) | 1976-07-12 | 1989-02-09 | Hoffmann La Roche | Soluzioni inietabili in cui l'atti vita' emolitica degli agenti di formazione di micelle naturali e' evitata mediante l'aggiunta di lipoidi e relativi prodotti |
| DE2914788A1 (de) | 1979-04-11 | 1980-10-16 | Nattermann A & Cie | Parenteral applizierbare, stabile arzneimittelloesungen mit entzuendungshemmender wirkung |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4412999A (en) | 1982-04-14 | 1983-11-01 | Merck & Co., Inc. | Anti-emetic esters of cyproheptadine-3-carboxylic acid and structurally related compounds |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| GB8424709D0 (en) | 1984-10-01 | 1984-11-07 | Minnesota Mining & Mfg | Azine redox dyes and leuco azine dyes |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4959217A (en) | 1986-05-22 | 1990-09-25 | Syntex (U.S.A.) Inc. | Delayed/sustained release of macromolecules |
| US4925678A (en) | 1987-04-01 | 1990-05-15 | Ranney David F | Endothelial envelopment drug carriers |
| US5080646A (en) | 1988-10-03 | 1992-01-14 | Alza Corporation | Membrane for electrotransport transdermal drug delivery |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5244925A (en) | 1987-12-18 | 1993-09-14 | Kabi Pharmacia Aktiebolag | Emulsion for parenteral administration |
| GB2228412B (en) | 1989-02-28 | 1993-04-14 | Syntex Inc | Nicardipine pharmaceutical composition for parenteral administration |
| IT1230881B (it) | 1989-06-20 | 1991-11-08 | Angeli Inst Spa | Derivati del r(-) 3-chinuclidinolo |
| US5167616A (en) | 1989-12-14 | 1992-12-01 | Alza Corporation | Iontophoretic delivery method |
| DK203990D0 (da) | 1990-08-24 | 1990-08-24 | Novo Nordisk As | Piperazinylderivater |
| US5225182A (en) | 1991-10-31 | 1993-07-06 | Sharma Yash P | Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system |
| US5434174A (en) | 1992-07-17 | 1995-07-18 | Eli Lilly And Company | Isoxazole derivatives for the treatment of irritable bowel syndrome |
| US5437291A (en) | 1993-08-26 | 1995-08-01 | Univ Johns Hopkins | Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction |
| US7048906B2 (en) | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
| WO1997002043A1 (en) | 1995-06-30 | 1997-01-23 | Novo Nordisk A/S | Prevention of a disease having the characteristics of diabetes |
| GB9606076D0 (en) | 1996-03-22 | 1996-05-22 | Univ Birmingham | Diabetes treatment |
| US6756056B2 (en) * | 1997-04-08 | 2004-06-29 | Alan A. Rubin | Treatment of Parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa |
| US7098232B1 (en) | 1999-10-22 | 2006-08-29 | Athpharma Limited | Treatment and prevention of gastrointestinal disease using antagonists of partial agonists of 5HT1a receptors |
| EP1235561A2 (en) * | 1999-11-30 | 2002-09-04 | Panacea Biotec Limited | Fast dissolving composition with prolonged sweet taste |
| US20030176421A1 (en) | 1999-12-30 | 2003-09-18 | Watson John W. | Prokinetic agents for treating gastric hypomotility and related disorders |
| US6239122B1 (en) | 2000-01-05 | 2001-05-29 | Joy Ann Steele | Method of treatment of nausea, vomiting, and other disorders using estrogens |
| PL361875A1 (en) | 2000-11-15 | 2004-10-04 | Tap Pharmaceutical Products, Inc. | Treatment of anti-depression drug-induced sexual dysfunction with apomorphine |
| US20020108869A1 (en) | 2001-02-09 | 2002-08-15 | Alex Savtchenko | Device and technique for multiple channel patch clamp recordings |
| US20070129307A1 (en) | 2001-06-22 | 2007-06-07 | The University Of British Columbia | Insulin epitopes for the treatment of type 1 diabetes |
| GB2389791B (en) | 2002-04-30 | 2006-12-13 | Steven Gill | Implantable drug delivery pump |
| FR2845914B1 (fr) | 2002-10-18 | 2005-11-04 | Schwarz Pharma Lab | Compose antiemetique a desagregation rapide |
| US7618948B2 (en) | 2002-11-26 | 2009-11-17 | Medtronic, Inc. | Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA |
| WO2004062623A2 (en) | 2003-01-13 | 2004-07-29 | Dynogen Pharmaceuticals, Inc. | Method of treating functional bowel disorders |
| US20040172084A1 (en) | 2003-02-03 | 2004-09-02 | Knudson Mark B. | Method and apparatus for treatment of gastro-esophageal reflux disease (GERD) |
| JP2006520777A (ja) | 2003-03-17 | 2006-09-14 | ファイザー・プロダクツ・インク | Ｐｄｅ５阻害剤を用いる１型糖尿病の治療 |
| CA2521369A1 (en) | 2003-04-08 | 2004-10-28 | Progenics Pharmaceuticals, Inc. | The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome |
| US8815950B2 (en) * | 2003-08-29 | 2014-08-26 | Janssen Biotech, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
| US7358271B2 (en) | 2003-09-05 | 2008-04-15 | Williamsburg Holdings Llc | Sulpiride pharmaceutical compositions |
| US20060287221A1 (en) | 2003-11-13 | 2006-12-21 | Novo Nordisk A/S | Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia |
| WO2006020930A2 (en) | 2004-08-12 | 2006-02-23 | Sapphire Therapeutics, Inc. | Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues |
| WO2006052626A2 (en) | 2004-11-03 | 2006-05-18 | The Board Of Regents Of The University Of Texas System | Dopamine 3 receptor agonist and antagonist treatment of gastrointestinal motility disorders |
| WO2006069276A2 (en) * | 2004-12-22 | 2006-06-29 | Janssen Pharmaceutica N.V. | TRICYCLIC ō-OPIOID MODULATORS |
| US20090054319A1 (en) | 2005-03-17 | 2009-02-26 | Microbia, Inc. | Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders |
| US20070016262A1 (en) | 2005-07-13 | 2007-01-18 | Betastim, Ltd. | Gi and pancreatic device for treating obesity and diabetes |
| WO2007022531A2 (en) | 2005-08-19 | 2007-02-22 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| WO2008002971A2 (en) | 2006-06-29 | 2008-01-03 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| PL2136801T3 (pl) | 2007-03-30 | 2013-01-31 | Tioga Pharmaceuticals Inc | Agoniści kappa-opioidów do leczenia zespołu jelita drażliwego w postaci zmiennej i z dominującą biegunką |
| MX2009011577A (es) * | 2007-04-26 | 2010-03-10 | Craig A Aronchick | Composiciones y metodos para distribucion de domperidona a traves de la mucosa. |
| WO2008141074A1 (en) | 2007-05-10 | 2008-11-20 | Salk Institute For Biological Studies | Identification of compounds that protect against amyloid diseases |
| US7930033B2 (en) | 2007-08-17 | 2011-04-19 | Jianfeng Chen | Appendicular and rectal stimulator device for digestive and eating disorders |
| US20090326004A1 (en) | 2008-06-03 | 2009-12-31 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
| ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
| JP5756105B2 (ja) * | 2009-07-31 | 2015-07-29 | クレラ インコーポレイティッド | パーキンソン病の治療のための組成物および方法 |
| ES2437921T3 (es) | 2009-10-21 | 2014-01-15 | Wisconsin Alumni Research Foundation | Método para prevenir la diabetes tipo 1 |
| US8417465B2 (en) | 2009-11-04 | 2013-04-09 | Cfd Research Corporation | Synthetic microfluidic blood-brain barrier |
| CN102781424B (zh) * | 2010-03-04 | 2016-03-30 | 奥赖恩公司 | 左旋多巴、卡比多巴和恩他卡朋用于治疗帕金森病的应用 |
| US8329009B2 (en) | 2010-04-09 | 2012-12-11 | Molecular Devices, Llc | High throughput screening of ion channels |
| JP5860457B2 (ja) | 2010-06-18 | 2016-02-16 | アルトス・セラピューティクス・リミテッド・ライアビリティ・カンパニーＡｌｔｏｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｌｌｃ | Ｄ２アンタゴニスト、その合成方法および使用方法 |
| US20120053121A1 (en) | 2010-08-31 | 2012-03-01 | Nationwide Children's Hospital, Inc. | Administration of HB-EGF for the Protection of Enteric Neurons |
| US20120101089A1 (en) | 2010-10-26 | 2012-04-26 | Ashwani Agarwal | Anti-Emetic Substance |
| WO2013028909A1 (en) | 2011-08-25 | 2013-02-28 | Sova Pharmaceuticals, Inc. | Combination therapy for the treatment of sleep-related breathing disorders |
| FR2980976B1 (fr) | 2011-10-10 | 2015-10-16 | Mohamed Skiba | Composition pharmaceutique pour l'administration par voie nasale de la metopimazine |
| AU2013370966A1 (en) | 2012-12-24 | 2015-06-18 | Neurogastrx, Inc. | Methods for treating GI tract disorders |
| IN2013MU02528A (enExample) | 2013-07-31 | 2015-06-26 | Centaur Pharmaceuticals Private Ltd | |
| WO2015200369A1 (en) | 2014-06-24 | 2015-12-30 | Neurogastrx, Inc. | Prodrugs of metopimazine |
-
2013
- 2013-12-19 AU AU2013370966A patent/AU2013370966A1/en not_active Abandoned
- 2013-12-19 CN CN201380067866.8A patent/CN104884064A/zh active Pending
- 2013-12-19 ES ES13869541T patent/ES2955693T3/es active Active
- 2013-12-19 CA CA2893427A patent/CA2893427C/en active Active
- 2013-12-19 JP JP2015549742A patent/JP6154025B2/ja active Active
- 2013-12-19 CA CA3178035A patent/CA3178035A1/en active Pending
- 2013-12-19 WO PCT/US2013/076733 patent/WO2014105655A1/en not_active Ceased
- 2013-12-19 EP EP13869541.6A patent/EP2934540B1/en active Active
- 2013-12-19 BR BR112015015258A patent/BR112015015258A2/pt not_active IP Right Cessation
-
2014
- 2014-11-26 US US14/555,455 patent/US9132134B2/en active Active
-
2015
- 2015-08-07 US US14/820,885 patent/US9808467B2/en active Active
-
2017
- 2017-05-31 JP JP2017108370A patent/JP6437593B2/ja active Active
- 2017-09-27 US US15/717,765 patent/US20180200258A1/en not_active Abandoned
-
2018
- 2018-11-14 JP JP2018213361A patent/JP2019048848A/ja active Pending
- 2018-12-11 US US16/216,257 patent/US20190314384A1/en not_active Abandoned
-
2020
- 2020-04-30 US US16/862,762 patent/US11147820B2/en active Active
-
2021
- 2021-02-12 JP JP2021021155A patent/JP2021088575A/ja active Pending
- 2021-09-17 US US17/477,830 patent/US20220202826A1/en not_active Abandoned
-
2023
- 2023-06-05 US US18/205,634 patent/US20240058353A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021088575A5 (enExample) | ||
| US6608088B1 (en) | Use of donerezil for the treatment of functional and/or organic pain syndromes | |
| IE58314B1 (en) | Pharmaceutical products providing enhanced analgasia | |
| RU2005134359A (ru) | Применение метилналтрексона для лечения синдрома раздраженного кишечника | |
| CN116509861A (zh) | 用于治疗偏头痛的拉司米地坦与cgrp拮抗剂的组合疗法 | |
| CN1137894A (zh) | 顽发克星在治疗妇女非抑郁下丘脑性经闭中的应用 | |
| JPH10513463A (ja) | うっ血性心不全の治療へのカルバゾール化合物の利用 | |
| KR20210147083A (ko) | 다발경화증 치료용 조합 요법 | |
| KR20090021214A (ko) | Ｃｇｒｐ-길항제에 의한 위장 장애의 치료 | |
| UA51615C2 (uk) | Застосування сполуки, що має капа опіатагоністичну активність та спосіб лікування | |
| US20040019101A1 (en) | Methods of treating gastrointestinary and genitourinary pain disorders | |
| JP2022009121A (ja) | 併存疾患としてアパシーを伴うアルツハイマー病の治療における使用のための５－ｈｔ６受容体アンタゴニスト | |
| JP2016507500A5 (enExample) | ||
| RU2351327C2 (ru) | Средство для лечения синдрома раздраженного кишечника с преобладанием диареи | |
| JP5905198B2 (ja) | 薬剤誘発性吐き気のオピオイド拮抗薬による治療 | |
| JPH02502546A (ja) | 抗ひきつけ剤組成物および方法のためのデキストロルファン相乗的協力剤 | |
| IE80774B1 (en) | Nmda antagonists | |
| EA019194B1 (ru) | Применение 4-циклопропилметокси-n-(3,5-дихлор-1-оксидопиридин-4-ил)-5-(метокси)пиридин-2-карбоксамида для лечения моторных нарушений, связанных с болезнью паркинсона | |
| HUP0200655A2 (hu) | Osanetant alkalmazása kedélyállapot-rendellenességek kezelésére használható gyógyszerek előállítására | |
| JP2020517670A (ja) | うつ病を治療するための組成物および方法 | |
| KR20160138301A (ko) | 브렉스피프라졸과 날메펜의 병용제 및 물질-관련 장애의 치료를 위한 이의 용도 | |
| JP3250921B2 (ja) | 腸管運動機能不全性疾患の治療剤 | |
| US20220211708A1 (en) | Pharmaceutical combination of pimozide and methotrexate and use thereof | |
| JP4695326B2 (ja) | 鼻炎用医薬組成物 | |
| JP2610735B2 (ja) | 抗鬱剤および抗ストレス剤組成物 |